Research Progress on Relation Between CD47 and Immunotherapy on Lymphoma
10.3971/j.issn.1000-8578.2021.21.0253
- VernacularTitle:CD47与淋巴瘤免疫治疗相关性的研究进展
- Author:
Yiyang LUO
1
;
Xiaoli FENG
Author Information
1. Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
- Publication Type:Research Article
- Keywords:
CD47;
SIRPα;
Immune escape;
Lymphoma;
Immunotherapy
- From:
Cancer Research on Prevention and Treatment
2021;48(8):799-803
- CountryChina
- Language:Chinese
-
Abstract:
CD47 is a member of the immunoglobulin superfamily. It is expressed on various cells and tissues of human, but it is more expressed on tumor cells, especially in various hematopoietic tumors. The combination of CD47 expressed on tumor cells with signal regulator protein α (SIRPα) on macrophages inhibits the phagocytosis of tumors by macrophages. The reaction can lead to tumor immune escape. CD47 has become a new hot spot in tumor research. This article reviews the correlation between the structure and expression of CD47, CD47-SIRPα, CD47-targeting antibody drugs and lymphoma immunotherapy.
